{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:16:33Z","timestamp":1792808193139,"version":"4.5.0"},"reference-count":57,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Key R&D Program of China","award":["2022YFF1502000"],"award-info":[{"award-number":["2022YFF1502000"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170181"],"award-info":[{"award-number":["82170181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["7222027"],"award-info":[{"award-number":["7222027"]}]},{"name":"Beijing Physician Scientist Training Project","award":["BJPSTP-2024-01"],"award-info":[{"award-number":["BJPSTP-2024-01"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,10,26]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CAR-T-cell therapy and bispecific antibody have revolutionized the treatment landscape for multiple myeloma. However, there is currently a lack of studies comparing the efficacy and safety of these two approaches. This meta-analysis assesses the efficacy and safety of B-cell maturation antigen (BCMA)-directed CAR-T-cell therapies and BCMA\u00d7CD3 bispecific antibodies as third-line or later interventions for relapsed\/refractory multiple myeloma (RRMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Web of Science, and Cochrane databases up to May 31, 2024, identifying 11 eligible studies encompassing 1269 participants. Random-effects models evaluated the primary (complete response (CR) rate) and secondary (overall response rate (ORR)) outcomes, while meta-regression analyses adjusted for relevant covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CAR-T-cell therapy achieved significantly higher pooled CR rate (0.54 (95% CI 0.42\u20130.69) vs bispecific antibodies 0.35 (0.30\u20130.41), p&lt;0.01) and pooled ORR (0.83 (0.76\u20130.90) vs 0.65 (0.59\u20130.71), p&lt;0.01). However, CAR-T therapy had a higher incidence of adverse events, particularly cytokine release syndrome (CRS 0.83 (0.70\u20130.97) vs bispecific antibodies 0.59 (0.43\u20130.74), p&lt;0.05). Severe CRS (grade \u22653) occurred at a rate of 0.07 (0.03\u20130.14) in the CAR-T cell group, contrasting with a negligible rate of 0.01 (0.00\u20130.02) in the bispecific antibody group (p&lt;0.01). Hematologic adverse events, including neutropenia (grade \u22653; 0.88 (0.81\u20130.95) vs 0.48 (0.30\u20130.67), p&lt;0.01) and anemia (grade\u22653; 0.55 (0.47\u20130.62) vs 0.34 (0.28 to 0.40), p&lt;0.01), were also more frequent in the CAR-T-cell group. Furthermore, differences in efficacy were observed among various CAR-T products, with ciltacabtagene autoleucel showing greater efficacy in CR rate (0.77 (0.71\u20130.84) vs 0.37 (0.32\u20130.41), p&lt;0.01) and ORR (0.91 (0.83\u20130.99) vs 0.73 (0.68\u20130.77), p&lt;0.01) compared with idecabtagene vicleucel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAR-T-cell therapy demonstrated superior CR rates compared with bispecific antibodies, although with an increase in severe adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010064","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T22:05:20Z","timestamp":1731881120000},"page":"e010064","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-3155","authenticated-orcid":false,"given":"Xiaojie","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China"},{"name":"Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9903-5428","authenticated-orcid":false,"given":"Yufan","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University Sixth Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0374-5724","authenticated-orcid":false,"given":"Baiwei","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3284-5887","authenticated-orcid":false,"given":"Bingyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1034-7425","authenticated-orcid":false,"given":"WeiXiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6374-1096","authenticated-orcid":false,"given":"Shengyu","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0858-0561","authenticated-orcid":false,"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shunde Hospital of Southern Medical University, Foshan, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-914X","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,17]]},"reference":[{"key":"2025100312213425000_12.11.e010064.1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2025100312213425000_12.11.e010064.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"2025100312213425000_12.11.e010064.3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2015.10.014","article-title":"SnapShot: Multiple Myeloma","volume":"28","author":"Braggio","year":"2015","journal-title":"Cancer Cell"},{"key":"2025100312213425000_12.11.e010064.4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00135-5"},{"key":"2025100312213425000_12.11.e010064.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"2025100312213425000_12.11.e010064.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122"},{"key":"2025100312213425000_12.11.e010064.7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"2025100312213425000_12.11.e010064.8","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"2025100312213425000_12.11.e010064.9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100312213425000_12.11.e010064.10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329"},{"key":"2025100312213425000_12.11.e010064.11","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100312213425000_12.11.e010064.12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-023-01479-5","article-title":"BCMA-targeted CAR-T cell therapies in relapsed and\/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting","volume":"16","author":"Wu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025100312213425000_12.11.e010064.13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-019-0823-5","article-title":"Chimeric antigen receptor T cell therapies for multiple myeloma","volume":"12","author":"Wu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025100312213425000_12.11.e010064.14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2021-147915","article-title":"Updated Results from MajesTEC-1: Phase 1\/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Moreau","year":"2021","journal-title":"Blood"},{"key":"2025100312213425000_12.11.e010064.15","doi-asserted-by":"crossref","unstructured":"Lesokhin AM , Arnulf B , Niesvizky R , et al . Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody. 2022;40:8006. doi:10.1200\/JCO.2022.40.16_suppl.8006","DOI":"10.1200\/JCO.2022.40.16_suppl.8006"},{"key":"2025100312213425000_12.11.e010064.16","first-page":"8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J C O"},{"key":"2025100312213425000_12.11.e010064.17","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: A Phase 1b\/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and\/or Refractory Multiple Myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"2025100312213425000_12.11.e010064.18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"2025100312213425000_12.11.e010064.19","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025100312213425000_12.11.e010064.20","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2025100312213425000_12.11.e010064.21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2203478"},{"key":"2025100312213425000_12.11.e010064.22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2025100312213425000_12.11.e010064.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"2025100312213425000_12.11.e010064.24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed\/Refractory Multiple Myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100312213425000_12.11.e010064.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"2025100312213425000_12.11.e010064.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"2025100312213425000_12.11.e010064.27","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"N Med"},{"key":"2025100312213425000_12.11.e010064.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100312213425000_12.11.e010064.29","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1002\/ajh.26745","article-title":"Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed\/refractory multiple myeloma","volume":"97","author":"Chen","year":"2022","journal-title":"Am J Hematol"},{"key":"2025100312213425000_12.11.e010064.30","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/bloodadvances.2024012967","article-title":"Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed\/refractory multiple myeloma","volume":"8","author":"Kfir-Erenfeld","year":"2024","journal-title":"Blood Adv"},{"key":"2025100312213425000_12.11.e010064.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"2025100312213425000_12.11.e010064.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162"},{"key":"2025100312213425000_12.11.e010064.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2224"},{"key":"2025100312213425000_12.11.e010064.34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"2025100312213425000_12.11.e010064.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025100312213425000_12.11.e010064.36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17460441.2024.2319672","article-title":"The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma","volume":"19","author":"Strassl","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"2025100312213425000_12.11.e010064.37","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.15"},{"key":"2025100312213425000_12.11.e010064.38","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025100312213425000_12.11.e010064.39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front Immunol"},{"key":"2025100312213425000_12.11.e010064.40","first-page":"17","article-title":"Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Exp Panel Opin from the Am Soc for Transplant and Cell Ther Transplant Cell Ther"},{"key":"2025100312213425000_12.11.e010064.41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025100312213425000_12.11.e010064.42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2025100312213425000_12.11.e010064.43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","article-title":"An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2025100312213425000_12.11.e010064.44","first-page":"S13","article-title":"Bispecific T-cell engagers for treatment of multiple myeloma","volume":"98 Suppl 2","author":"Ravi","year":"2023","journal-title":"Am J Hematol"},{"key":"2025100312213425000_12.11.e010064.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741058"},{"key":"2025100312213425000_12.11.e010064.46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2025100312213425000_12.11.e010064.47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol Cancer"},{"key":"2025100312213425000_12.11.e010064.48","doi-asserted-by":"crossref","unstructured":"Thomas C , Ailawadhi S , Popat R , et al . n.d. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom. 10:1271657. doi:10.3389\/fmed.2023.1271657","DOI":"10.3389\/fmed.2023.1271657"},{"key":"2025100312213425000_12.11.e010064.49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"2025100312213425000_12.11.e010064.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.025"},{"key":"2025100312213425000_12.11.e010064.51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100312213425000_12.11.e010064.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.478"},{"key":"2025100312213425000_12.11.e010064.53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414"},{"key":"2025100312213425000_12.11.e010064.54","doi-asserted-by":"crossref","first-page":"215949","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett"},{"key":"2025100312213425000_12.11.e010064.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992"},{"key":"2025100312213425000_12.11.e010064.56","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"2025100312213425000_12.11.e010064.57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:21:46Z","timestamp":1759519306000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,17]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/jitc-2024-010064"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010064","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}